The fervency for advancement and evolution in percutaneous coronary intervention has revolutionised the treatment of coronary artery disease. Historically, the focus of the interventional cardiologist was directed at the restoration of luminal patency of the major epicardial coronary arteries, yet whilst this approach is evolving with much greater utilisation of physiological assessment, it often neglects consideration of the role of the coronary microcirculation, which has been shown to clearly influence prognosis. In this review, we explore the narrative of the coronary circulation as more than just a simple conduit for blood but an organ with functional significance. We review organisation and physiology of the coronary circulation, as well as the current methods and techniques used to examine it. We discuss the studies exploring coronary artery endothelial function, appreciating that coronary artery disease occurs on a spectrum of disorder and that percutaneous coronary intervention has a latent effect on the coronary circulation with long-term consequences. It is concluded that greater recognition of the coronary artery endothelium and mechanisms of the coronary circulation should further guide revascularisation strategies.
Background and Aims: A randomized trial has previously demonstrated that neointimal modification with a scoring balloon improves the anti‐restenotic effect of drug‐coated balloon (DCB) in patients with drug‐eluting stent restenosis. There are very limited data about the safety and efficacy of using scoring balloons as part of lesion preparation in patients with STEMI, especially in patients with de novo disease treated with DCB‐only angioplasty. Methods: We undertook an analysis of the SPARTAN Norwich Registry to address this question. We compared the composite endpoint of cardiovascular mortality or unplanned target lesion revascularization in the DCB‐only cohort stratified based on the use or not of scoring balloon as part of the lesion preparation. Furthermore, we undertook a propensity score‐matched analysis of the DCB‐only cohort. Results: A total of 452 consecutive patients were treated with DCB‐only angioplasty and scoring balloon was used in 121 patients as part of the lesion preparation. Scoring balloon was not a significant predictor of the composite endpoint even after propensity score‐matched analysis. Chronic obstructive pulmonary disease was the only significant predictor of the composite endpoint after propensity score‐matched analysis. Conclusion: This is the first study demonstrating the safety and efficacy of scoring balloon as part of lesion preparation in patients with STEMI due to de novo disease treated with DCB‐only angioplasty. Trial Registration: https://clinicaltrials.gov/ct2/show/NCT04482972 ; Unique identifier: NCT04482972.
19 March 2025 in JACC: Cardiovascular Interventions
Introduction In the setting of primary percutaneous coronary intervention (PPCI), it has been shown that stenting compared to balloon angioplasty (BA) reduces the need for repeat revascularisation but not overall mortality. A recent, small randomised trial showed that drug coated balloon (DCB) angioplasty for PPCI was non-inferior to drug eluting stent (DES) in terms of fractional flow reserve at 9 months. Our aim was to investigate the safety of DCB angioplasty in a STEMI population in terms of all-cause mortality. Methods We identified all patients treated for STEMI in our institution from January 2016 until November 2019. We excluded patients who died in hospital and patients with cardiac arrest, cardiogenic shock or requiring intubation; given that their mortality is more likely to be determined by the severity of their clinical presentation rather than the PCI strategy. The primary endpoint was all-cause mortality. Survival data were obtained through the UK Health and Social Care Information Service. Clinical and angiographic data were collected from our prospectively collated database and supplemented from electronic records where required. All angiograms were reviewed by an experienced operator to confirm treatment strategy, bifurcation lesions, coronary artery dissection and TIMI flow pre- and post-intervention. Results A total of 1190 patients were identified; 470 treated with DCB and 720 with DES. The average age for the DCB group was 65.5 ± 12.5 years old (73.6% male); while for the DES group it was 65.5 ± 11.6 years old (74.7% males). The average follow up was 882 ± 439 days and 978 ± 426 days for the DCB and DES group respectively. There were a few differences between the groups (table 1). There were no differences in all other clinical and angiographic characteristics. The all-cause mortality was 33/470 (7%) for the DCB group and 48/720 (6.7%) for the DES group. Kaplan Meier estimator plot for all-cause mortality (figure 1) did not show a significant difference between DCB and DES (p=0.54). On multivariable Cox regression analysis (table 2), age, prior stroke, coronary artery bypass graft, heart failure, chronic obstructive pulmonary disease (COPD) and diabetes were significant poor predictors of mortality. Conclusion Our real-world data from a large, contemporary cohort of STEMI patients demonstrate that DCB only angioplasty is safe compared to DES and may be considered as a treatment option. Conflict of Interest none
28 October 2025 in Catheterization and Cardiovascular Interventions
Background: The treatment of coronary bifurcation lesions (CBL) remains complex and associated with a higher rate of long‐term adverse cardiovascular events due to anatomical and procedural complexity. Aims: We compared procedural outcomes between a drug coated balloon (DCB) only approach and a 2nd generation drug eluting stent (DES) for treating de novo CBLs. Methods: We retrospectively identified all patients with CBL treated with either a DCB only or DES only strategy, including all coronary bifurcations and compared a bifurcation‐oriented composite endpoint (BOCE) of cardiovascular death, target bifurcation‐related myocardial infarction (TB‐MI), and clinically driven target bifurcation revascularization (TBR) using nationally obtained clinical outcome measures from 2015 to 2019. A propensity score matched analysis was undertaken. Results: Of 2113 patients, 1030 patients were treated with a DCB and 1083 with a DES. There was higher lesion complexity in the DCB group, and propensity score‐matched analysis was utilized. This included a total of 2052 patients (1026 in each arm). The median age was 68 (59−75), and all clinical presentations were included. The median follow‐up time was 3.6 (2.5−4.8) years with 501 (48.8%) patients having follow‐up available at 5 years. Propensity matched analysis showed a significant increase in events (14.0% vs. 9.9% respectively) (HR: 1.39 [1.08−1.79], p = 0.01) when using DES compared to DCB, driven predominantly by an increase in TBR (8.9% vs. 5.0%) (HR: 1.79 [1.27−2.50], p ≤ 0.001) and TB‐MI (3.0% vs. 1.6%) (HR: 1.92 [1.05−3.57], p 0.03). Conclusions: The use of DCB‐only in a coronary bifurcation is a safe alternative in treating CBL, within the limitations of a retrospective single center analysis. An appropriately designed RCT is now required.